Samyang Biopharmaceuticals Corporation   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Seoul Korea, Republic of (2011)
Status: No NME R&D (2011)

Organization Overview

First Clinical Trial
2011
NCT00877253
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Samyang Biopharmaceuticals Corporation

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Breast Neoplasms (Phase 3)

Carcinoma (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Hyperlipidemias (Phase 1)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 2)

Mycoses (Phase 1)

Neoplasms (Phase 1)

Neuralgia (Phase 2)

Neuralgia, Postherpetic (Phase 2)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 1)

Peripheral Nerve Injuries (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Urinary Bladder Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 21
  • # of Trial APIs: 18